TCR mimic compounds for pHLA targeting with high potency modalities in oncology

Area of Science:

• Oncology
• Immunology
• Biotechnology

Background:

• Peptide-MHC class I (pHLAs) are abundant cancer cell surface markers, making them key targets for cancer therapies.
• TCR mimics (TCRm) are engineered protein binders that recognize pHLAs, enabling targeted delivery of potent therapeutics like bispecifics and CAR T-cells.

Purpose of the Study:

• To review advanced strategies for engineering TCRm with high binding affinity and specificity for pHLA targets.
• To discuss the clinical status of TCRm-based therapeutics and identify challenges and future trends in oncology.

Main Methods:

• Affinity and specificity engineering of T-cell receptors (TCRs), antibodies, and alternative protein scaffolds.
• Analysis of current TCRm-based therapeutic development in the clinic.

Main Results:

• TCRm compounds leverage the tumor-specific nature of pHLA targets, including cancer-testis antigens (CTAs).
• Achieving high affinity and specificity in TCRm is critical for potent anti-tumor activity.

Conclusions:

• Advanced engineering approaches are vital for optimizing TCRm-based cancer therapies.
• Further development is needed to overcome challenges and improve treatment options for cancer patients.